Marco Meglio

A greater proportion of those treated with EVT had modified Rankin Scale scores of 0-3 at 90 days and NIHSS improvements of at least 8 points or more at 48 hours, relative to standard medical therapy.

The phase 4 study will evaluate the efficacy and safety of once-monthly injectable galcanezumab compared with every-other-day rimegepant taken orally.

The artificial neural network demonstrated an area under the precision-recall curve of 0.92 with recall of 0.72 with precision of 0.39 during testing, all values that were greater than classic regression models.

After small studies suggested eptifibatide may be safe in acute ischemic stroke, new data showed similar rates of ICH between study drug and controls, but increased PH-2 for those treated with the antiplatelet.

Relative to pre-pandemic era, the odds of mortality in stroke-related admissions increased during the pandemic, with an even greater risk for those less than 70 years of age.

Almost 40% of the studies assess did not report racial or ethnic subgroup data. Geographically, there was a slight increase in the number of South American-based phase 3 DMT trials and almost little-to-no improvement in the phase 3 DMT studies based in Africa.

The director of Cleveland Clinic’s Epilepsy Center discussed the new Cleveland Clinic Brain Study, which will evaluate predisease fingerprints from patients who go on to develop neurological disorders.

Relative to other PD-related genetically associated groups, only those with LRRK2-associated PD demonstrated a significantly increased risk of stroke compared with controls.

In previous phase 1 settings, CY6463 has demonstrated an impact on biomarkers relevant to neurodegeneration and cognitive impairment.

This was the first study to demonstrate a preventive treatment signal in migraine when an approved oral CGRP receptor antagonist is dosed as needed for the acute treatment of migraine.

Frail people or those with lower cognitive reserve were the only variables that benefitted from higher doses, whereas APOE status and education had no significant interaction.

At the 2-year time point, more than 40% of preadolescent and approximately 55% of adolescent patients retained treatment with perampanel after initiation during routine clinical care.

After changes were made to the AVATAR phase 3 study in Rett syndrome, Anavex provided context on the timing of the adjustments, which were approved by regulatory bodies in the UK and Australia, where the trial was conducted.

Most child neurologist respondents were generally early in their career, had diverse subspeciality training, and tended to work at large, resource-rich centers capable of multimodal neuromonitoring.

Treatment with blarcamesine resulted in statistically significant improvements on the new primary end point and significantly reduced Rett syndrome symptoms through changes in potential biomarkers of disease pathology.

The cognitive neurologist at the University of California, San Francisco provided insight on the research needed to explain more about COVID-19’s pathogenesis and the realistic possibility of developing neurocognitive disorders.

A greater proportion of patients treated with 0.25 mg/kg of tenecteplase were free from disability or achieved functional independence compared with those treated with 0.40 mg/kg doses, or alteplase.

Regardless of baseline body mass index, patients who had increases or decreases of 5% or more in BMI had faster cognitive decline over a 5-year follow-up period.

Overall, more than 40% of the cohort were eligible for a migraine preventive medication, but only 16.8% reported currently using one.

In addition to improving constipation in patients with Parkinson disease, ENT-01 also helped improve Mini-Mental State Examination scores, an exploratory measure of cognition.

Take a look at 5 of the most-anticipated clinical trial data readouts expected in 2022 that neurology health care professionals should keep their eyes on.

Chronic medical comorbidities, more commonly found in patients with obstructive sleep apnea, have been associated with higher readmission and healthcare utilization rates.

At 10 minutes post dose, all 3 AZ-009 dose groups showed a clear reduction from baseline in mean MDS-UPDRS part III score that was greater than for placebo.

After adjusting for baseline scores, no significant correlation emerged between the changes on Epworth Sleepiness Scale and the number of hours of CPAP use.

The recurrence of ischemic stroke was less common with dual antiplatelet therapy than with monotherapy in those treated within the 15–180-day window, and similarly common in the 8–14-day period.

The cognitive neurologist at the University of California, San Francisco discussed recently published data on the presence of cognitive post-acute sequelae of COVID-19 and the need to legitimize these conditions.

Approximately 300 patients across 30 clinical centers will be included in the 36-week study evaluating the efficacy and safety of sodium oligomannate (GV-971), a medication currently approved for Alzheimer disease in China.

Device-related adverse events were reported in less than 1% of the safety analysis population, which included more than 100,000 patients with migraine who were treated with Nerivio.

Patients on the study drug demonstrated improvements in several different exploratory cardiac end points, including NT-proBNP and echocardiographic parameters relative to placebo.

The trial will also include another investiartional Eisai agent, the antiamyloid therapy lecanemab, as the background study drug to evaluate the true effect of E2814 has on patients with dominantly inherited Alzheimer disease.